Appears on
Articles3
Genentech lays off 103 alongside gRED rethink, pens $490M breast cancer collab
A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed that this has formed part of a round of 103 layoffs.
0
Fierce Biotech3d agoScribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.
0
Fierce Biotech5d agoScipher picks up Chemomab’s liver disease drug, Nasdaq listing in all-stock merger
Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech’s liver disease drug as the ideal fit for its own expertise.
0
Fierce Biotech17h ago